Endometriosis-Related Pain Reduction During Bleeding and Nonbleeding Days in Women Treated with Elagolix
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In this post hoc analysis, we evaluated the impact of elagolix on dysmenorrhea and nonmenstrual pelvic pain across menstrual period (bleeding days) and nonmenstrual (nonbleeding) days. METHODS: Data from two randomized, 6-month, placebo-controlled trials (Elaris Endometriosis (EM)-I and EM-II) of elagolix (150 mg once daily (QD) and 200 mg twice daily (BID)) in premenopausal women with moderate to severe endometriosis-associated pain (N = 1686) were pooled. Women recorded the presence of menstrual period and severity of dysmenorrhea or nonmenstrual pelvic pain in a daily electronic diary. RESULTS: At baseline, women in the placebo group and both elagolix treatment groups reported moderate or severe dysmenorrhea, on average, 81% of their menstrual period days and moderate/severe nonmenstrual pelvic pain, on average, 56% of their nonmenstrual (nonbleeding) days. Compared with placebo at month 6, elagolix-treated women had a significantly lower mean (standard deviation (SD)) percentage of menstrual period days with moderate or severe dysmenorrhea (elagolix 150 mg QD = 52.4 (38.9), p = 0.002; elagolix 200 mg BID = 38.5 (43.6), p < 0.001, placebo = 61.3 (33.7)) and a significantly lower mean (SD) percentage of nonmenstrual (nonbleeding) days with moderate or severe nonmenstrual pelvic pain (elagolix 150 mg QD = 31.1 (35.8), p < 0.001; elagolix 200 mg BID = 19.7 (29.9), p < 0.001; placebo = 35.6 (33.9)). CONCLUSION: Following 6 months of elagolix treatment, women who still menstruated had a lower proportion of menstrual period days with moderate or severe dysmenorrhea compared with placebo, demonstrating pain reduction despite continued menses. Additionally, pain did not shift from dysmenorrhea to nonmenstrual pelvic pain, as the percentage of days with moderate or severe nonmenstrual pelvic pain was also reduced for elagolix-treated women compared with placebo. TRIAL REGISTRATION: The Elaris EM-I study is registered with the US National Library of Medicine, www.ClinicalTrials.gov, NCT01620528. The Elaris EM-II study is registered with the US National Library of Medicine, www.ClinicalTrials.gov, NCT01931670. Both studies are registered with the EU Clinical Trial Register, www.clinicaltrialsregister.ed, 2011-004295-11.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Also in women who still menstruated, a lower proportion of menstrual period days with moderate or severe dysmenorrhea compared with placebo was shown, indicating pain reduction despite continued menses [174].”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [174]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endometriosis: pathogenesis and treatment
Vercellini, P., Viganò, P., Somigliana, E., & Fedele, L. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.255 · Cited by 1,940 · cited 1×
“It is probable that endometriosis gives rise to multiple different types of pain including nociceptive, inflammatory, and neuropathic pain, either alone or in combination, and that different pain pathways may be responsible for the different types of pain experienced by women because of endometriosis.(16)”
BackgroundGiudice, L. C. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp1000274 · Cited by 1,924
Pathogenesis and pathophysiology of endometriosis
Burney, R. O., & Giudice, L. C. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.06.029 · Cited by 1,590
World Endometriosis Society consensus on the classification of endometriosis
Johnson, N. P., Hummelshoj, L., Adamson, G. D., Keckstein, J., Taylor, H. S., Abrao, M. S., Bush, D., Kiesel, L., Tamimi, R., Sharpe-Timms, K. L., et al. (2017) · Human Reproduction · doi:10.1093/humrep/dew293 · Cited by 664
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Taylor, H. S., Giudice, L. C., Lessey, B. A., Abrao, M. S., Kotarski, J., Archer, D. F., Diamond, M. P., Surrey, E., Johnson, N. P., Watts, N. B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700089 · Cited by 511 · cited 8×
“Results from two placebo-controlled, Phase III studies (Elaris Endometriosis I (EM-I) and Elaris Endometriosis II (EM-II)) demonstrated that 6 months of elagolix treatment with either 150 mg once daily (QD) or 200 mg twice daily (BID) doses resulted in clinically significant dosedependent reductions in dysmenorrhea an…”
BackgroundMethodSelf-citationDiagnostic experience among 4,334 women reporting surgically diagnosed endometriosis
Greene, R., Stratton, P., Cleary, S. D., Ballweg, M. L., & Sinaii, N. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.11.020 · Cited by 327
Fuldeore, M. J., & Soliman, A. M. (2017) · Gynecologic and Obstetric Investigation · doi:10.1159/000452660 · Cited by 266
Mechanisms of pain in endometriosis
Morotti, M., Vincent, K., & Becker, C. M. (2017) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2016.07.497 · Cited by 255 · cited 2×
“The severity of this pain may also fluctuate, and is rarely constant.(15) It is probable that endometriosis gives rise to multiple different types of pain including nociceptive, inflammatory, and neuropathic pain, either alone or in combination, and that different pain pathways may be responsible for the different typ…”
BackgroundThe direct and indirect costs associated with endometriosis: a systematic literature review
Soliman, A. M., Yang, H., Du, E. X., Kelley, C., & Winkel, C. (2016) · Human Reproduction · doi:10.1093/humrep/dev335 · Cited by 239
Soliman, A. M., Coyne, K. S., Zaiser, E., Castelli-Haley, J., & Fuldeore, M. J. (2017) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.1080/0167482x.2017.1289512 · Cited by 166
Research works printed but not linked: 1
- Ng J, Klein CE, Carter DC, Chwalisz K. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102(5):1683–1691. doi:10.1210/jc.2016-3845 · DOI · Paper page
Cited by
Hormonal treatments for endometriosis: The endocrine background
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09666-w · Cited by 336
Ali, M. K., Sara, A. R., & Hendy, A. A. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1900726 · Cited by 34
Abrão, M. S., Surrey, E. S., Gordon, K., Snabes, M. C., Wang, H., Ijacu, H., & Taylor, H. S. (2021) · BMC Women s Health · doi:10.1186/s12905-021-01385-3 · Cited by 19
“These data are consistent with a recent study demonstrating a reduction in pain during bleeding and nonbleeding days after 6 months of treatment with both low and high dosages of elagolix [28].”
ResultSelf-citationHorizons in Endometriosis: Proceedings of the Montreux Reproductive Summit, 14-15 July 2023
Vallée, A., Sarıdoğan, E., Petraglia, F., Keckstein, J., Polyzos, N. P., Wyns, C., Gianaroli, L., Tarlatzis, B. C., Ayoubi, J. M., & Féki, A. (2024) · Facts Views and Vision in ObGyn · doi:10.52054/fvvo.16.s1.011 · Cited by 11
Current Status of the Therapeutic Approach for Dysmenorrhea
Cortés, H., Hernández‐Parra, H., Bernal-Chávez, S. A., Caballero-Florán, I. H., Aguilar-Vázquez, R., Prado-Audelo, M. L. D., González‐Torres, M., Reyes‐Hernández, O. D., Figueroa‐González, G., & Leyva‐Gómez, G. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.3.7 · Cited by 9
Role of hormonal therapies in endometriosis: balancing efficacy and safety
Ferrero, S., Paudice, M., Perrone, U., Rosato, F. P., Gullo, G., Vellone, V. G., & Barra, F. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2685064 · Cited by 7
Palumbo, M., Giampaolino, P., Pellicano, M., Graziano, V., Bifulco, G., & Corte, L. D. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2657998 · Cited by 4
“Dienogest remains the most affordable medical therapy for endometriosis in many healthcare systems, often covered under public reimbursement schemes [20,55,56].”
Tapkan, C., SÜTCÜOĞLU, B. M., Öncü, H. N., & İbanoğlu, M. C. (2022) · Türk Kadın Sağlığı ve Neonatoloji Dergisi · doi:10.46969/ezh.1167744 · Cited by 1
“It is a severe uterine bleeding episode that may require immediate intervention to prevent hemodynamic instability (3).”
BackgroundRashidpour, F., Farzanegi, P., & Abbaszadeh, H. (2022) · Journal of Sports Physiology and Athletic Conditioning · doi:10.61186/jspac.39258.2.6.31
Abrao, M. S., Surrey, E. S., Gordon, K., Snabes, M. C., Wang, H., Ijacu, H., & Taylor, H. S. (2021) · Figshare · doi:10.6084/m9.figshare.14795093
Self-citation
Metadata
- Authors
- Agarwal, S. K., Singh, S. S., Archer, D. F., Mai, Y., Chwalisz, K., Gordon, K., & Surrey, E.
- Affiliations
- University of California San Diego (US)
- Ottawa Hospital Research Institute (CA)
- Eastern Virginia Medical School (US)
- AbbVie (United States) (US)
- Colorado Center for Reproductive Medicine (US)
- Corresponding author
- Agarwal, Sanjay K
- Venue
- Journal of Pain Research
- Publisher
- Informa UK Limited
- Published
- 2021-02
- Volume
- Volume 14
- Pages
- 263-271
- ISSN
- 1178-7090 (ISSN-L)
- PMC
- PMC7866925
- OpenAlex
- W3128524842
- Cited by
- 11
- References
- 16
- Citations by year
- 2026: 2 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 4
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Pain Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Funders
- Pfizer
- Teva Pharmaceutical Industries
- AbbVie
- Radius Health
- Bayer HealthCare
- Shionogi
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Menstrual Health and Disorders
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Keywords
- endometriosis, elagolix, dysmenorrhea, menstrual bleeding, analgesia, premenopausal women, endometriosis-associated pain, dose comparison, post hoc analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.